Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Urothelial cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    240 result(s) found for: Urothelial cancer. Displaying page 3 of 12.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2020-005565-13 Sponsor Protocol Number: 17000139BLC2002 Start Date*: 2021-10-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    21.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001394-16 Sponsor Protocol Number: GCT1029-01 Start Date*: 2018-03-29
    Sponsor Name:Genmab B.V.
    Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1029 in patients with malignant solid tumors
    Medical condition: Malignant solid tumors: Patients with advanced and/or metastatic colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), renal cell carcinoma (RCC), gastr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004340-11 Sponsor Protocol Number: 17403 Start Date*: 2018-06-13
    Sponsor Name:Bayer AG
    Full Title: A randomized, open label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or me...
    Medical condition: mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Prematurely Ended) FR (Completed) AT (Completed) CZ (Completed) ES (Completed) PT (Completed) FI (Completed) SK (Completed) HU (Completed) DK (Completed) BE (Completed) SE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004367-12 Sponsor Protocol Number: FCR173009 Start Date*: 2019-10-02
    Sponsor Name:Fundación CRIS de investigación para vencer el cáncer
    Full Title: A phase I-II study to evaluate the efficacy and safety of niraparib in combination with cabozantinib (XL184) in patients with advanced urothelial cancer after failure to first-line platinum-based c...
    Medical condition: Urinary tract or renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-000857-35 Sponsor Protocol Number: UC-EGFR_INT01 Start Date*: 2015-03-31
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: An open label, randomized, phase 2 study of Paclitaxel and Panitumumab compared to Paclitaxel alone in patients with relapsed or refractory urothelial cancer.
    Medical condition: relapsed/refractory Metastatic urothelial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006501-30 Sponsor Protocol Number: MINOTAURO Start Date*: Information not available in EudraCT
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, multicentre, phase 2 trial: minotaURO study
    Medical condition: Patients with metastatic urothelial carcinoma in treatment with pembrolizumab, as clinically indicated, beyond the First RECIST-defined progression who have a stable performance status and demonst...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003680-11 Sponsor Protocol Number: PRESURGY/01/2015 Start Date*: 2015-12-15
    Sponsor Name:PRESURGY S.L.
    Full Title: Impact of the mitomicin-C (MMC) preoperative administration in patients with primary urothelial non-muscle invasive (TVNMI) bladder cancer using electromotive instillation (EMDA). Prospective rando...
    Medical condition: Impact of the mitomicin-C (MMC) preoperative administration in patients with primary urothelial non-muscle invasive bladder cancer (TVNMI) using electromotive instillation (EMDA). Prospective rando...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004165-58 Sponsor Protocol Number: GO39590 Start Date*: 2017-02-21
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF MOXR0916 IN COMBINATION WITH ATEZOLIZUMAB VERSUS ATEZOLIZUMAB ALONE IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR ME...
    Medical condition: Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000695-28 Sponsor Protocol Number: VitDURO-AECC17-01 Start Date*: 2018-07-04
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: Pilot study of Vitamin D biological effects in patients with resectable urinary tract urothelial carcinoma.
    Medical condition: Patients with resectable urinary tract urothelial carcinoma candidates to radical cystectomy o nephroureterectomy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046718 Urothelial carcinoma bladder stage I, with cancer in situ LLT
    20.0 100000004864 10046720 Urothelial carcinoma bladder stage II LLT
    20.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    20.0 100000004864 10046724 Urothelial carcinoma ureter local LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004017-27 Sponsor Protocol Number: EUOG-2016-003 Start Date*: 2019-05-08
    Sponsor Name:European Uro-Oncology Group (EUOG)
    Full Title: "Neo-adjUvant veRsus AdjuvaNt chemotherapy in Upper Tract Urothelial Carcinoma: A feaSibility phase II randomized clinical trial (“URANUS”)
    Medical condition: Patients with upper urinary tract transitional cell carcinoma (UTUC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004542-15 Sponsor Protocol Number: SGN22E-003 Start Date*: 2020-08-03
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally a...
    Medical condition: Urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005427-10 Sponsor Protocol Number: 1200.261 Start Date*: 2016-04-29
    Sponsor Name:Boehringer Ingelheim España, S.A.
    Full Title: Phase II open label single arm exploratory trial of oral afatinib monotherapy following platinum failure for patients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregula...
    Medical condition: patients with advanced/metastatic urothelial tract carcinoma with ERBB receptor deregulation
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-002826-55 Sponsor Protocol Number: SECAVIN-12 Start Date*: 2012-10-17
    Sponsor Name:Associació Per a la Recerca Oncològica (APRO)
    Full Title: A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium
    Medical condition: metastatic or locally advanced transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003249-25 Sponsor Protocol Number: ATLANTIS_2015 Start Date*: 2016-11-28
    Sponsor Name:NHS Greater Glasgow & Clyde [...]
    1. NHS Greater Glasgow & Clyde
    2. University of Glasgow
    Full Title: An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer.
    Medical condition: Metastatic urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10061620 Adenocarcinoma with transitional cell carcinoma of bladder LLT
    21.0 100000004864 10001213 Adenocarcinoma with transitional cell carcinoma of bladder NOS LLT
    21.1 100000004864 10001214 Adenocarcinoma with transitional cell carcinoma of bladder recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-000559-15 Sponsor Protocol Number: FB2012 Start Date*: 2012-09-14
    Sponsor Name:FinnBladder
    Full Title: TREATMENT OF Ta BLADDER CANCER WITH HIGH RISK OF RECURRENCE – FLUORESCENCE CYSTOSCOPY WITH OPTIMIZED ADJUVANT MITOMYCIN-C
    Medical condition: bladder cancer (non-invasive Ta urothelial bladder cancer)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-004070-34 Sponsor Protocol Number: PRECAVE Start Date*: 2018-01-29
    Sponsor Name:Servicio de Urología. Hospital Universitario La Paz
    Full Title: RANDOMIZED CLINICAL TRIAL, OPEN, TO EVALUATE THE BLADDER INSTILLATION OF NEOADYUVANT CHEMOTHERAPY TO THE TRANSURETHAL RESECTION OF BLADDER FOR THE PREVENTION OF RECURRENCE OF NONMUSCLE-INVASIVE URO...
    Medical condition: Non-muscle-invasive urothelial carcinoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000205-24 Sponsor Protocol Number: G1T28-209 Start Date*: 2021-10-28
    Sponsor Name:G1 Therapeutics, Inc.
    Full Title: A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered with First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients with Untreated, Locally Advanced or Meta...
    Medical condition: Untreated, Locally Advanced or Metastatic Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000294-67 Sponsor Protocol Number: CA209-6L6 Start Date*: 2022-12-21
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase II Study of Adjuvant Nivolumab Switch from Intravenous (IV) to Subcutaneous (SC) Use in Participants with Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma ...
    Medical condition: Stage III A/B/C/D, Stage IV melanoma or Muscle-Invasive Urothelial Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004494-41 Sponsor Protocol Number: CLIN2001UCM301 Start Date*: 2021-06-11
    Sponsor Name:Steba Biotech, S.A.
    Full Title: Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
    Medical condition: Low Grade Upper Tract Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    20.0 100000004864 10046375 Ureter cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005603-25 Sponsor Protocol Number: WO29636 Start Date*: 2015-07-30
    Sponsor Name:Roche Farma, S.A., que representa en España a F. Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF MPDL3280A (ANTI-PD-L1 ANTIBODY) VERSUS OBSERVATION AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED, HIGH RISK MUSCLE INVASIVE BLADDER C...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10022877 Invasive bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FI (Completed) CZ (Completed) DE (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 08:53:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA